Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fish oil and BP

This article was originally published in The Tan Sheet

Executive Summary

Supplemental n-3 fatty acids "had no significant effect on blood pressure" in healthy subjects age 30-65 during a three-month period, a study in the February American Journal of Clinical Nutrition finds. The controlled, multi-center trial followed 162 subjects who were placed either on a diet rich in monounsaturated fatty acids (MUFA), or one rich in saturated fatty acids (SFA). The two diet groups were split in half again and given either 3.6 grams n-3 fatty acids or placebo; blood pressure was measured at baseline and at the end of the study. Both systolic and diastolic blood pressure decreased on the MUFA diet, while no significant changes occurred for those on the SFA diet. "Addition of n-3 fatty acids did not influence systolic blood pressure or diastolic blood pressure...regardless of whether they were consuming a high-fat or a low-fat diet," Birthe Rasmussen, Department of Clinical Endocrinology, Aarhus University Hospital, Denmark, et al., conclude...

You may also be interested in...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?

“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts